GleamWall
中文EN

FATE FATE THERAPEUTICS INC

Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1434316 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY-33.4%
TTM net income YoY20.3%
TTM EPS YoY22.6%
Revenue 3-yr CAGR-64.5%
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-2,760.0%
Net margin-2,619.6%
FCF margin-2,249.4%
EBITDA margin-2,519.2%

Returns

ROE-67.8%
ROA-42.8%
ROIC (approx.)-73.3%
Asset turnover0.02x

Leverage & solvency

Liabilities / assets44.2%
Debt / equity0.00x
Current ratio4.41x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.85x
Accruals ratio-6.6%
Payout ratio—
Capex / revenue31.8%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$2.08M$1.30M$1.37M$1.74M$1.91M$1.63M$1.86M
R&D expense$24.21M$24.39M$24.70M$25.43M$25.84M$27.43M$29.14M$33.61M
SG&A expense$8.03M$8.83M$9.60M$10.66M$10.64M$11.45M$13.77M$15.26M
Operating income-$32.25M-$31.13M-$33.00M-$34.72M-$34.73M-$36.97M-$41.28M-$61.75M
Net income-$30.69M-$30.16M-$31.21M-$32.37M-$32.25M-$34.07M-$37.62M-$52.15M
EBITDA-$29.57M-$28.35M-$30.08M-$31.66M-$31.51M-$33.69M-$37.95M-$56.94M
EPS (basic)-0.25-0.25-0.26—-0.27-0.29-0.32—
EPS (diluted)-0.25-0.25-0.26—-0.27-0.29-0.32—
Weighted avg. shares (diluted)123.66M120.40M120.03M—119.00M118.53M118.38M—
Balance sheet
Cash & equivalents$43.94M$32.43M$39.57M$46.63M$40.62M$41.25M$44.92M$36.06M
Short-term investments$95.19M$121.34M$135.25M$157.03M$174.80M$181.58M$195.50M$243.01M
Receivables$479,000$703,000$704,000$916,000$682,000$1.40M$2.41M$3.54M
Current assets$144.26M$157.95M$179.53M$208.70M$221.25M$230.40M$248.22M$291.91M
PP&E, net$48.91M$51.55M$54.26M$56.92M$59.48M$61.10M$62.76M$64.38M
Total assets$238.28M$260.10M$284.92M$318.94M$343.67M$371.63M$398.67M$440.69M
Current liabilities$32.69M$32.59M$30.69M$36.07M$28.11M$28.67M$28.16M$38.52M
Total liabilities$105.24M$106.67M$105.21M$111.75M$109.61M$110.27M$110.26M$121.97M
Shareholders' equity$133.03M$153.44M$179.71M$207.18M$234.07M$261.36M$288.41M$318.73M
Shares outstanding121.53M116.69M116.27M115.36M115.34M114.66M114.60M113.93M
Cash flow statement
Operating cash flow-$27.80M-$23.40M-$30.82M-$23.31M-$24.37M-$24.59M-$33.81M-$27.80M
Capital expenditure$0$80,000$239,000$1.19M$2.20M$1.36M$1.20M$98,000
Free cash flow-$27.80M-$23.48M-$31.06M-$24.51M-$26.58M-$25.95M-$35.01M-$27.90M
Investing cash flow$26.84M$14.56M$23.59M$27.63M$21.27M$19.59M$42.67M$22.82M
Financing cash flow$7.62M——$1.69M$2.48M$1.32M$0$3.13M
Depreciation & amortization$2.68M$2.78M$2.92M$3.06M$3.23M$3.28M$3.33M$4.81M
Stock-based compensation$2.70M$3.52M$3.93M$5.53M$4.86M$7.15M$7.38M$9.12M

Free plan shows the latest 8 periods; Pro shows all 59 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.